Suppr超能文献

肾上腺素与去甲肾上腺素在心肺复苏后休克患者中的应用比较。

Epinephrine versus norepinephrine in cardiac arrest patients with post-resuscitation shock.

机构信息

Paris Cardiovascular Research Center (PARCC), INSERM Unit 970, Paris, France.

Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, Massy, France.

出版信息

Intensive Care Med. 2022 Mar;48(3):300-310. doi: 10.1007/s00134-021-06608-7. Epub 2022 Feb 7.

Abstract

PURPOSE

Whether epinephrine or norepinephrine is preferable as the continuous intravenous vasopressor used to treat post-resuscitation shock is unclear. We assessed outcomes of patients with post-resuscitation shock after out-of-hospital cardiac arrest according to whether the continuous intravenous vasopressor used was epinephrine or norepinephrine.

METHODS

We conducted an observational multicenter study of consecutive patients managed in 2011-2018 for post-resuscitation shock. The primary outcome was all-cause hospital mortality, and secondary outcomes were cardiovascular hospital mortality and unfavorable neurological outcome (Cerebral Performance Category 3-5). A multivariate regression analysis and a propensity score analysis were performed, as well as several sensitivity analyses.

RESULTS

Of the 766 patients included in five hospitals, 285 (37%) received epinephrine and 481 (63%) norepinephrine. All-cause hospital mortality was significantly higher in the epinephrine group (OR 2.6; 95%CI 1.4-4.7; P = 0.002). Cardiovascular hospital mortality was also higher with epinephrine (aOR 5.5; 95%CI 3.0-10.3; P < 0.001), as was the proportion of patients with CPC of 3-5 at hospital discharge. Sensitivity analyses produced consistent results. The analysis involving adjustment on a propensity score to control for confounders showed similar findings (aOR 2.1; 95%CI 1.1-4.0; P = 0.02).

CONCLUSION

Among patients with post-resuscitation shock after out-of-hospital cardiac arrest, use of epinephrine was associated with higher all-cause and cardiovascular-specific mortality, compared with norepinephrine infusion. Until additional data become available, intensivists may want to choose norepinephrine rather than epinephrine for the treatment of post-resuscitation shock after OHCA.

摘要

目的

在治疗心肺复苏后休克时,连续静脉使用肾上腺素或去甲肾上腺素作为血管加压药,哪种更优尚不清楚。我们评估了院外心脏骤停后复苏后休克患者的结局,根据连续静脉使用的血管加压药是肾上腺素还是去甲肾上腺素进行分组。

方法

我们进行了一项多中心观察性研究,纳入了 2011 年至 2018 年期间管理的复苏后休克连续患者。主要结局是全因院内死亡率,次要结局是心血管院内死亡率和不良神经结局(脑功能分级 3-5 级)。进行了多变量回归分析和倾向评分分析,以及几项敏感性分析。

结果

在纳入的 5 家医院的 766 例患者中,285 例(37%)接受肾上腺素治疗,481 例(63%)接受去甲肾上腺素治疗。肾上腺素组的全因院内死亡率显著更高(OR 2.6;95%CI 1.4-4.7;P=0.002)。使用肾上腺素的心血管院内死亡率也更高(aOR 5.5;95%CI 3.0-10.3;P<0.001),出院时脑功能分级为 3-5 级的患者比例也更高。敏感性分析得出了一致的结果。涉及调整倾向评分以控制混杂因素的分析也显示了类似的发现(aOR 2.1;95%CI 1.1-4.0;P=0.02)。

结论

在院外心脏骤停后复苏后休克患者中,与去甲肾上腺素输注相比,使用肾上腺素与全因和心血管特定死亡率增加相关。在获得更多数据之前,重症监护医生可能希望选择去甲肾上腺素而不是肾上腺素来治疗院外心脏骤停后的复苏后休克。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验